Early life vitamin D and neurocognitive abilities at age 6-8 years: a randomized clinical trial and observational analysis.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Participants were from a Finnish vitamin D double-blind randomized clinical trial and classified themselves white.

Serum 25(OH)D was analyzed from mothers at mean of 11.2 weeks of gestation, and from children at 12.0 and 23.9 months (25(OH)D, mean (SD) = 83.8 (21.7), 102.3 (30.1), 105.5 (28.6) nmol/L, respectively).

Who Took Part

By PubMed's age tags, the people studied were infants, young children and children, both men and women.

Total Intelligence quotient (IQ) score was assessed with Wechsler Intelligence Scale for Children (WISC-IV) and executive functioning with A Developmental Neuropsychological Assessment (NEPSY-II) and parent-rated Behavior Rating Inventory of Executive Function (BRIEF) questionnaire.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

What Was Measured

PubMed files the paper under topics including Vitamin D, Child Development, Executive Function, Dietary Supplements, Cholecalciferol, Finland and Neuropsychological Tests.

Author keywords: 25(OH)D, Children and Neurocognitive abilities.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2026 (European child & adolescent psychiatry), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.